base significantly, resulting in a net profit attributable to the Company of Baht 3.59 million (in proportion to the shareholding) for this business of producing and selling dialysis and pharmaceuticals
2018 amounted to Baht 226 million and the administrative expenses to revenue from main business accounted for 13%, which was not significantly changed from the same period of prior year. Finance cost The
assets the depreciation in H1 and Q2 is significantly above last year. Finance cost has increased as expected with the main increase coming from the interest on the new 330mTHB facility used for the
The Company had gross profit for the third quarter of 2018 amounting to Baht 229 million, which was not significantly changed from the same period of last year. Gross profit margin for the third quarter
significantly transaction changes. 2. Cost of sale , Profit margin For Quarter 2 of the year 2020, the company had cost of sale of 98.72 million bath compare to 93.54 million baht last year with the increasing of
Expenses 1,148.8 2,103.6 1,123.0 (954.8) (45.4%) 25.8 2.3% Profit for the period 59.7 132.8 102.8 (73.1) (55.0)% (43.1) (41.9)% Overall, the global economy is likely to slow down significantly due to the
Company’s project transferred during 2Q19 climbed up significantly. Down payment at 15-20% possibly plays a vital role in reducing portion of speculative buyers in our projects, minimizing negative impact
Expenses 1,148.8 2,103.6 1,123.0 (954.8) (45.4%) 25.8 2.3% Profit for the period 59.7 132.8 102.8 (73.1) (55.0)% (43.1) (41.9)% Overall, the global economy is likely to slow down significantly due to the
. • Net profit margin in Q1/2020 dropped by 15.0% from Q1/2019 as a result of the slow down in dessert café sales in Q1/2020 while SG&A expenses did not change significantly as the cost-saving plan will be
2020 which the Company’s performance was adversely impacted by COVID-19 pandemic. For this year, with the easing supply of the semiconductor, significantly higher volume from our major customers, new car